Author, year | No.pts | Age mean/SD (year) | BMI mean/SD (kg/m2) | Treatment, duration | Control group | Type of surgical, No. of cycles | Fresh/frozen sperm | Spouse’s age (year) | Outcomes (PR, FR, IR) and final outcome (LBR) | Adverse events |
---|---|---|---|---|---|---|---|---|---|---|
Female | ||||||||||
Ulug 2005 | 58 | 32.2/5.2 | 21.09/1.3 | HCG, HMG, | TI | IUI, IVF (ICSI)-ET, 53 cycles | n/a | n/a | PR 56.6%, | abortion, |
14 days | n = 16 | FR 73.9%, | multiple pregnancy | |||||||
IR 32.4% | ||||||||||
Kumbak 2006 | 27 | 32.8/4.9 | 25.7/4.5 | gonadotrophins, | UI | IVF (ICSI)-ET, | n/a | n/a | PR 59.3%, | multiple pregnancy |
14 days | n = 39 | 27 cycles | FR 89%, | |||||||
IR 36.5% | ||||||||||
Yildirim 2010 | 13 | 31.3/5.6 | 25.3/3.1 | gonadotrophins, | TI | IVF (ICSI)-ET, | n/a | n/a | PR 80%, | abortion |
13 days | n = 20 | 13 cycles | FR 81.9%, | |||||||
IR 38.3%, | ||||||||||
LBR 50% | ||||||||||
Dokuzeylul 2010 | 57 | ≤37 | n/a | gonadotrophins, | normal control | IVF (ICSI)-ET, | n/a | n/a | PR 56.14%, | n/a |
14 days | n = 95 | 57 cycles | IR 36.7% | |||||||
Caragia 2012 | 17 | 32.96/3.976 | n/a | FSH, LH, | TI/MI/UI | IVF (ICSI)-ET, | n/a | n/a | PR 55.6%, | no adverse events |
16 days | N = 56/56/56 | 28 cycles | FR 55.4%, | |||||||
LBR 54% | ||||||||||
Ghaffari 2013 | 81 | 33.5/5.3 | 26.1/4.0 | HMG, HCG, P, E2, | TI | IVF (ICSI)-ET, | n/a | n/a | PR 19.4%, | abortion, |
14 days | n = 89 | 72 cycles | FR 61.2%, | multiple pregnancy | ||||||
IR 40%, | ||||||||||
LBR 15.2% | ||||||||||
Pandurangi 2015 | 7 | 27 | 25.29/3.77 | HMG, uFSH, | n/a | IUI, IVF (ICSI)-ET, 19 cycles | n/a | n/a | PR 31.6%, | abortion, |
29 days | FR 85%, | multiple pregnancy | ||||||||
LBR 85.7% | ||||||||||
Yilmaz 2015 | 33 | 32.5/4.73 | 26/ 3.81 | HMG, HCG, recFSH, P,12 days | MI | IVF (ICSI)-ET, | n/a | n/a | PR 30% | n/a |
n = 47 | 33 cycles | |||||||||
Jiang 2017 | 46 | 30.9/3.9 | 21.26/1.89 | HCG, HMG, | TI | IUI, IVF (ICSI)-ET, 42 cycles | n/a | n/a | PR 59.52%, | abortion, |
13 days | n = 71 | FR 82.13%, | multiple pregnancy | |||||||
IR 41.46% | ||||||||||
Mumusoglu 2017 | 57 | 30.6/5.1 | 25.6/4.5 | FSH, | TI | IVF (ICSI)-ET, | n/a | n/a | PR 36.8%, | abortion |
11 days | n = 114 | 57 cycles | IR 34.4%, | |||||||
LBR 36.8% | ||||||||||
Kuroda 2018 | 79 | 32.6/0.5 | 18/0.3 | HCG, HMG, | n/a | IVF (ICSI)-ET, | n/a | n/a | PR 59.3%, | abortion |
12.2 days | 117 cycles | LBR 45.9% | ||||||||
Male | ||||||||||
Fahmy 2004 | 15 | 38.71/6.2 | n/a | HCG, HMG, | n/a | TESE+IVF (ICSI)-ET, | n/a | n/a | PR 16.7%, | multiple pregnancy |
6 months | 17 cycles | FR 41.7% | ||||||||
Zorn 2005 | 4 | 37.75 | n/a | HCG, HMG, | n/a | IVF (ICSI)-ET, | fresh/ | 31.5 | PR 33.3%, | no adverse events |
13.25 months | 9 cycles | frozen sperm | IR 21% | |||||||
Bakircioglu 2007 | 25 | 34.5/5.2 | n/a | HCG, | n/a | TESE+IVF (ICSI)-ET, | fresh/ | n/a | PR 54.5% | abortion |
9.96 months | 22 cycles | frozen sperm | ||||||||
Akarsu 2009 | 4 | 36.25 | n/a | HCG, HMG, | n/a | TESE+IVF (ICSI)-ET, | fresh/ | 29.5 | PR 16.7%, | abortion, |
9.96 months | 18 cycles | frozen sperm | FR 41.8%, | multiple pregnancy | ||||||
LBR 75% | ||||||||||
Resorlu 2009 | 17 | 30.1 | n/a | HCG, FSH, | n/a | IVF (ICSI)-ET, | fresh | n/a | PR 54.5% | n/a |
24 months | 11 cycles | sperm | ||||||||
Dokuzeylul 2010 | 31 | 34.82 | n/a | HCG, HMG, | n/a | TESE+IVF (ICSI)-ET, | n/a | n/a | PR 51.7%, | abortion, |
6 months | 29 cycles | FR 83%, | multiple pregnancy | |||||||
LBR 41.3% | ||||||||||
Bakircioglu 2012 | 12 | 40.2 | n/a | HCG, FSH, | n/a | TESE+IVF (ICSI)-ET, | n/a | n/a | PR 66.7%, | multiple pregnancy |
15.3 months | 9 cycles | LBR 77.8% | ||||||||
Sahin 2012 | 65 | n/a | n/a | gonadotrophins, | n/a | IVF (ICSI)-ET, | n/a | n/a | PR 43.9%, | n/a |
10.2 months | 57 cycles | LBR 60% | ||||||||
Basar 2017 | 61 | 35.8/5.64 | n/a | HCG, HMG, | n/a | TESE+IVF (ICSI)-ET, | fresh/ | n/a | PR 47.1%, | n/a |
n/a | 119 cycles | frozen sperm | LBR 62.3% |